Bear,,  I am just noting that DM has not had a great history of meeting time lines or estimating costs,,,,,,,here is a 2014 news blurb from RVX,,;

Nov. 03, 2014,

""As we continue the development of RVX-208 for chronic diseases like CVD and diabetes mellitus, Michael brings highly relevant clinical development experience to our company," said Donald McCaffrey, president and chief executive officer of Resverlogix. " as we prepare for the initiation of the Phase 2/3 trial of RVX-208 in patients with CVD and diabetes mellitus. We are set to begin enrolling patients in the first half of 2015 and plan additional trials to evaluate the drug in other conditions like Alzheimer's disease, peripheral artery disease, and chronic kidney disease."

With an anticipated first half of 2015 for enrollment I get end of 2017 for completion of this trial based on the 2.5/3 year guesstimate. DM stated we were set to enroll first half of '15. Albeit this is a news release dated in Nov. of '14, imo it was a well understood point from DM that summer where this Pll/lll trial was to be concluded end of 2017. I think we all understood the same at that time. So we are presently heading into 2019 within days and BoM is near the end but not yet ended. And I wont even chat about what DM anticipated for trial costs here. We all know that history as it continues to this day. Imagine what timing we would have if the trial had taken on emrollment in the US,,,,time and costs!!